CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
MP-424 (Telaprevir)drug
Likely dose
MP-424 (Telaprevir) 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00621296
NCT00621296Phase 2Completed
CompareCT.gov

Phase II Study of MP-424 in Patients With (Genotype 1b) Hepatitis C

Tanabe Pharma Corporation·interventional·Posted Feb 22, 2008·Updated Jan 6, 2026

In Brief

A Phase 2 clinical trial evaluating MP-424 (Telaprevir) for Hepatitis C. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesJapan
CollaboratorsVertex Pharmaceuticals Incorporated

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 22, 2008
Enrollment StartJan 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.4 years ago

Interventions

MP-424 (Telaprevir)drug

Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)